TrialReader


Dietary Interventions and Butyrate Production in Behçet's Patients

NCT03274648 — Not applicable, Completed, 17 participants, Azienda Ospedaliero-Universitaria Careggi

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Therapeutic Modulation of Butyrate Production in Behçet's Patients: a Dietary Intervention Trial

RegistryNCT03274648
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: none, treatment
Enrollment17 (Actual)
SponsorAzienda Ospedaliero-Universitaria Careggi (Other)
ConditionsBehcet Syndrome
InterventionsOral butyrate, Vegetarian diet, Habitual diet (Dietary supplement)
Datesstart 2017-09-27, primary completion 2019-05-01, completion 2019-07-05, first posted 2017-09-07, last updated 2020-01-28
Locations1 site in Italy

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Behcet Syndrome All trials of Oral butyrate All trials of Vegetarian diet

-Summary

A dietary intervention trial will be performed on patients affected by Behçet's syndrome. Three different diets will be compared, analyzing their effects on the gut microbiota composition, on endogenous butyrate production and on the general symptoms in Behçet's patients.

Expand all sections  ·  Collapse all

+Detailed description

A dietary intervention trial will be conducted with the use of three different diets in order to compare the effects of these diets on the gut microbiota composition, on endogenous butyrate production and on the general symptoms in Behçet's patients.

The study will be a randomized, open trial designed to test whether a vegetarian diet or an habitual diet supplemented with oral butyrate would benefit the butyrate production, the gut microbiota composition and the general symptoms of Behçet's patients, compared with the habitual diet.

The study will involve 30 subjects with Behçet syndrome. Patients will be randomly assigned to follow a 3-months isocaloric dietary profile with either:

* vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
* habitual diet supplemented with 2.4g/day of oral butyrate
* habitual diet without supplementation At the baseline visit, subjects will be educated about the aims and methods of the clinical trial and will sign their informed consent form.

Anthropometric measurements, body composition, and blood and stool sampling will be obtained from each participant at the beginning and at the end of the intervention period. All subjects will be examined between 07.00 and 09.30 hours after a 12 h fasting period.

The following parameters will be analyzed both at the beginning and at the end of the intervention period:

* Complete blood count
* Lipid variables - total cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides
* Glycemic profile - glucose, insulin, glycated hemoglobin (HbA1C), HOMA index
* Liver function tests - aspartate aminotransferase (AST), alanine transaminase (ALT), gammaglutamyl transferase (GGT), alkaline phosphatase (ALP), albumin, prealbumin
* Kidney function tests - serum creatinine, urea, uric acid
* Mineral profile - sodium, potassium, magnesium, calcium
* Iron metabolism - iron, ferritin
* Vitamin profile - vitamin B12, folic acid, vitamin D
* Thyroid function - TSH
* Inflammatory markers - erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA)
* Serology for celiac disease - IgA, anti-transglutaminase antibodies (IgA), anti endomysium antibodies (IgA)
* Circulating levels of inflammatory cytokines
* Oxidative stress markers
* Gut microbiota composition
* Butyrate production

At the beginning and at the end of the intervention period, participants will be asked to complete a questionnaire, which will assess Behçet's symptoms frequency and severity. In addition, participants will be contacted by phone to complete a 24-hours recall in order to test the adherence to diets they have been assigned to.

+Arms and interventions

ArmTypeInterventionsDescription
vegetarian dietExperimentalDietary Supplement: Vegetarian dietvegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
Habitual diet + oral butyrateExperimentalDietary Supplement: Oral butyratehabitual diet supplemented with 2.4g/day of oral butyrate
Habitual dietActive comparatorDietary Supplement: Habitual diethabitual diet without supplementation
  • Oral butyrate (Dietary supplement): Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
  • Vegetarian diet (Dietary supplement): Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
  • Habitual diet (Dietary supplement): Patients follow the habitual diet

+Outcome measures

Primary outcomes

  • Evaluation of gut microbiota composition [0-3 months]
  • Evaluation of butyrate production [0-3 months]: For the extraction of SCFAs (and butyrate in particular) the method described in Schnorr et al. will be follow" \[Schnorr SL, Candela M, Rampelli S, Centanni M, Consolandi C, Basaglia G,et al. Gut microbiome of the Hadza hunter-gatherers. Nat Commun 2014;5:3654\]
  • Complete blood count [0-3 months]: composite score
  • Lipid variables [0-3 months]: composite score taking into account the levels of: total cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides
  • Glycemic profile [0-3 months]: composite score taking into account the levels of : glucose, insulin, glycated hemoglobin (HbA1C), HOMA index
  • Vitamin profile [0-3 months]: composite score, taking into account the levels of: vitamin B12, folic acid, vitamin D
  • Liver function tests [0-3 months]: composite score taking into account the levels of: aspartate aminotransferase (AST), alanine transaminase (ALT), gammaglutamyl transferase (GGT), alkaline phosphatase (ALP), albumin, prealbumin
  • Kidney function tests [0-3 months]: composite score taking into account the levels of : serum creatinine, urea, uric acid
  • Mineral profile [0-3 months]: composite score taking into account the levels of: sodium, potassium, magnesium, calcium
  • Iron metabolism [0-3 months]: composite score taking into account the levels of: iron, ferritin
  • Thyroid function [0-3 months]: measurement of TSH levels
  • Inflammatory markers [0-3 months]: composite score taking into account the levels of: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA)
  • Serology for celiac disease [0-3 months]: composite score taking into account the levels of: IgA, anti-transglutaminase antibodies (IgA), anti endomysium antibodies (IgA)
  • Circulating levels of inflammatory cytokines [0-3 months]: composite score
  • Oxidative stress markers [0-3 months]: composite score

Secondary outcomes

  • Evaluation Behçet's symptoms frequency and severity [0-3 months]: Participants are asked to complete a questionnaire, which will assess Behçet's symptoms frequency and severity.

+Eligibility

Sex: All, ages: 18 Years to 70 Years

Inclusion Criteria:

* All patients affected by Behçet's disease

Exclusion Criteria:

* Pregnancy or breastfeeding
* Presence of diabetes mellitus
* Presence of other immune-mediated diseases
* Presence or history of cancer in the last 5 years
* Presence of infectious diseases in the last 3 months
* No antibiotic therapy in the last 3 months
* No vegetarian or vegan diet
* No intake of pro- or pre-biotics in the last 3 months

+Locations (1)

FacilityCityCountryStatus
AOU CareggiFlorenceItaly

+Publications

  • Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behcet's disease: a review. World J Gastroenterol. 2015 Apr 7;21(13):3801-12. doi: 10.3748/wjg.v21.i13.3801. PMID 25852265
  • Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, Biagi E, Grassi A, Rampelli S, Silvestri E, Centanni M, Cianchi F, Gotti R, Emmi L, Brigidi P, Bizzaro N, De Bellis G, Prisco D, Candela M, D'Elios MM. Behcet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015 Apr;14(4):269-76. doi: 10.1016/j.autrev.2014.11.009. Epub 2014 Nov 27. PMID 25435420
  • Wong JM. Gut microbiota and cardiometabolic outcomes: influence of dietary patterns and their associated components. Am J Clin Nutr. 2014 Jul;100 Suppl 1:369S-77S. doi: 10.3945/ajcn.113.071639. Epub 2014 Jun 4. PMID 24898225

My Notes